ACTINEX
LOE Approachingmasoprocol
NDATOPICALCREAM
Approved
Sep 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTINEX (masoprocol) is a topical cream approved in 1992 for treatment of actinic keratosis, a precancerous skin condition caused by sun exposure. The drug's mechanism of action and pharmacologic class are not well-documented in available literature. It represents a niche dermatology product with limited modern clinical development.
LOE Approaching
As LOE approaches, the commercial team is likely right-sizing and exploring life-cycle management opportunities; modest portfolio impact expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ACTINEX offers limited career growth potential due to its LOE-approaching status and minimal linked job openings; positions are typically maintenance-focused rather than launch or expansion. This product may appeal to professionals seeking stable, established portfolio experience rather than high-growth opportunities.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.